Condition: Peripheral T Cells Lymphoma (PTCL) · Sponsor: Xenothera SAS
This is a 2-part study consisting of a Part 1, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), or Recommended Part 2 Dose (RP2D) of LIS1 as a single agent; followed by a Part 2, to investigate anti-tumors efficacy of LIS1 in selected subtypes of Peripheral TCell Lymphoma (PTCL) and to further evaluate its safety and tolerability at RP2D.
This description comes directly from the study's public registry record.
Françoise SHNEIKER, MD · +33652720301 · francoise.shneiker@xenothera.com
Alain BALEYDIER · +33672800375 · alain.baleydier@xenothera.com
Always discuss trial participation with your own doctor first.
| CHU de Caen | Caen, France | Recruiting |
| CHU de Clermont-Ferrand | Clermont-Ferrand, France | Recruiting |
| CHU Henri-Mondor | Créteil, France | Recruiting |
| CHU de Bordeaux - GH Sud - Hôpital Haut-Lévêque | Pessac, France | Recruiting |
| CHU de Lyon - Hôpital Lyon Sud | Pierre-Bénite, France | Recruiting |
| SC Ematologia Istituto Nazionale dei TumoriIRCCS Fondazione "G. Pascale" | Naples, Campania, Italy | Recruiting |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola | Bologna, Emilia-Romagna, Italy | Recruiting |
| Fondazione IRCCS Istituto Nazionale dei Tumori | Milan, Lombardy, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06495723